Emerging therapeutic targets in schwannomas and other merlin-deficient tumors

Nature Reviews Neurology

Volumn 7, Issue 7, 2011, Pages 392-399

  Ammoun, Sylwia ^a   Hanemann, C Oliver ^a  

^a PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; IMATINIB; LAPATINIB; MERLIN; NILOTINIB; PICROPODOPHYLLIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SOMATOMEDIN C RECEPTOR; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ACOUSTIC NEURINOMA; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CELL FUNCTION; DRUG EFFICACY; EPENDYMOMA; GLIOBLASTOMA; HUMAN; MENINGIOMA; NEURILEMOMA; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SCHWANN CELL; SIGNAL TRANSDUCTION;

HUMANS; NERVOUS SYSTEM NEOPLASMS; NEURILEMMOMA; NEUROFIBROMIN 2; RECEPTOR, ERBB-2; RECEPTOR, IGF TYPE 1; RECEPTORS, GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 79960107083     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2011.82     Document Type: Review

References (106)

1. Hanemann, C. O. & Evans, D. G. News on the genetics, epidemiology, medical care and translational research of schwannomas. J. Neurol. 253, 1533-1541 (2006 (Pubitemid 46115433)
2. Evans, D. G., Sainio, M. & Baser, M. E. Neurofibromatosis type 2. J. Med. Genet. 37, 897-904 (2000 (Pubitemid 32002885)
3. Tzahar, E. & Yarden, Y. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim. Biophys. Acta 1377, M25-M37 (1998 (Pubitemid 28144426)
4. Bange, J., Zwick, E. & Ullrich, A. Molecular targets for breast cancer therapy and prevention. Nat. Med. 7, 548-552 (2001 (Pubitemid 32448320)
5. Wickremesekera, A., Hovens, C. M. & Kaye, A. H. Expression of ErbB-1 and 2 in vestibular schwannomas. J. Clin. Neurosci. 14, 1199-1206 (2007 (Pubitemid 350102794)
6. Anglesio, M. S. et al. Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol. Cancer Res. 6, 1678-1690 (2008
7. Groenen, L. C., Nice, E. C. & Burgess, A. W. Structure-function relationships for the EGF/ TGF-alpha family of mitogens. Growth Factors 11, 235-257 (1994
8. Toyoda, H., Komurasaki, T., Ikeda, Y., Yoshimoto, M. & Morimoto, S. Molecular cloning of mouse epiregulin, a novel epidermal growth factor-related protein, expressed in the early stage of development. FEBS Lett. 377, 403-407 (1995 (Pubitemid 26027157)
9. Lonardo, F. et al. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. New Biol. 2, 992-1003 (1990
10. Beerli, R. R. et al. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol. Cell Biol. 15, 6496-6505 (1995
11. Karunagaran, D. et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J. 15, 254-264 (15-1-1996
12. Stern, D. F. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J. Mammary Gland Biol. Neoplasia 13, 215-223 (2008
13. Garratt, A. N., Britsch, S. & Birchmeier, C. Neuregulin, a factor with many functions in the life of a Schwann cell. Bioessays 22, 987-996 (2000
14. Birchmeier, C. & Nave, K. A. Neuregulin-1, a key axonal signal that drives Schwann cell growth and differentiation. Glia 56, 1491-1497 (2008
15. Shah, N. M., Marchionni, M. A., Isaacs, I., Stroobant, P. & Anderson, D. J. Glial growth factor restricts mammalian neural crest stem cells to a glial fate. Cell 77, 349-360 (1994 (Pubitemid 24145196)
16. Meyer, D. & Birchmeier, C. Multiple essential functions of neuregulin in development. Nature 378, 386-390 (1995
17. Dong, Z. et al. Neu differentiation factor is a neuron-glia signal and regulates survival, proliferation, and maturation of rat Schwann cell precursors. Neuron 15, 585-596 (1995
18. Syroid, D. E. et al. Cell death in the Schwann cell lineage and its regulation by neuregulin. Proc. Natl Acad. Sci. USA 93, 9229-9234 (1996 (Pubitemid 26282046)
19. Marchionni, M. A. et al. Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature 362, 312-318 (1993 (Pubitemid 23101302)
20. Lee, K. F. et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378, 394-398 (1995
21. Meier, C., Parmantier, E., Brennan, A., Mirsky, R. & Jessen, K. R. Developing Schwann cells acquire the ability to survive without axons by establishing an autocrine circuit involving insulin-like growth factor, neurotrophin-3, and platelet-derived growth factor-BB. J. Neurosci. 19, 3847-3859 (1999 (Pubitemid 29222261)
22. Riese, D. J., van Raaij, T. M., Plowman, G. D., Andrews, G. C. & Stern, D. F. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol. Cell Biol. 15, 5770-5776 (1995
23. Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2, 127-137 (2001 (Pubitemid 33674041)
24. Beeser, A., Jaffer, Z. M., Hofmann, C. & Chernoff, J. Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors. J. Biol. Chem. 280, 36609-36615 (2005 (Pubitemid 41587737)
25. Prenzel, N., Fischer, O. M., Streit, S., Hart, S. & Ullrich, A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr. Relat. Cancer 8, 11-31 (2001 (Pubitemid 32520251)
26. Arteaga, C. L., Moulder, S. L. & Yakes, F. M. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin. Oncol. 29, 4-10 (2002 (Pubitemid 34816060)
27. Zhang, H. et al. ErbB receptors: from oncogenes to targeted cancer therapies. J. Clin. Invest. 117, 2051-2058 (2007 (Pubitemid 47224766)
28. Gullick, W. J. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br. Med. Bull. 47, 87-98 (1991
29. Mischel, P. S. et al. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 22, 2361-2373 (2003 (Pubitemid 36566791)
30. Andersson, U. et al. Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol. 108, 135-142 (2004 (Pubitemid 39136299)
31. Pinkas-Kramarski, R. et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 15, 2452-2467 (1996 (Pubitemid 26151185)
32. Goldman, R., Levy, R. B., Peles, E. & Yarden, Y. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry 29, 11024-11028 (1990
33. Ben-Levy, R., Paterson, H. F., Marshall, C. J. & Yarden, Y. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J. 13, 3302-3311 (1994 (Pubitemid 24226945)
34. Klapper, L. N. et al. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 14, 2099-2109 (1997 (Pubitemid 27237013)
35. Riethmacher, D. et al. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature 389, 725-730 (1997 (Pubitemid 27458958)
36. Houshmandi, S. S., Emnett, R. J., Giovannini, M. & Gutmann, D. H. The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner. Mol. Cell Biol. 29, 1472-1486 (2009
37. Ammoun, S., Flaiz, C., Ristic, N., Schuldt, J. & Hanemann, C. O. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer Res. 68, 5236-5245 (2008
38. Prayson, R. A., Yoder, B. J. & Barnett, G. H. Epidermal growth factor receptor is not amplified in schwannomas. Ann. Diagn. Pathol. 11, 326-329 (2007 (Pubitemid 47380435)
39. Doherty, J. K., Ongkeko, W., Crawley, B., Andalibi, A. & Ryan, A. F. ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy. Otol. Neurotol. 29, 50-57 (2008
40. Stonecypher, M. S., Chaudhury, A. R., Byer, S. J. & Carroll, S. L. Neuregulin growth factors and their ErbB receptors form a potential signaling network for schwannoma tumorigenesis. J. Neuropathol. Exp. Neurol. 65, 162-175 (2006
41. Wickremesekera, A., Hovens, C. M. & Kaye, A. H. Expression of ErbB-1 and ErbB-2 in meningioma. J. Clin. Neurosci. 17, 1155-1158 (2010
42. Curto, M., Cole, B. K., Lallemand, D., Liu, C. H. & McClatchey, A. I. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J. Cell Biol. 177, 893-903 (2007 (Pubitemid 46873094)
43. Hansen, M. R. & Linthicum, F. H. Jr. Expression of neuregulin and activation of erbB receptors in vestibular schwannomas: possible autocrine loop stimulation. Otol. Neurotol. 25, 155-159 (2004 (Pubitemid 39079844)
44. Brown, K. D. & Hansen, M. R. Lipid raft localization of ErbB2 in vestibular schwannoma and schwann cells. Otol. Neurotol. 29, 79-85 (2008
45. Lallemand, D. et al. Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. Oncogene 28, 854-865 (2009
46. Thaxton, C., Lopera, J., Bott, M. & Fernandez-Valle, C. Neuregulin and laminin stimulate phosphorylation of the NF2 tumor suppressor in Schwann cells by distinct protein kinase A and p21-activated kinase-dependent pathways. Oncogene 27, 2705-2715 (2008 (Pubitemid 351581460)
47. Ammoun, S. et al. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol. 12, 834-843 (2010
48. Schaefer, G., Shao, L., Totpal, K. & Akita, R. W. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. Cancer Res. 67, 1228-1238 (2007
49. Clark, J. J. et al. The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. Otol. Neurotol. 29, 846-853 (2008
50. Eccleston, P. A., Funa, K. & Heldin, C. H. Expression of platelet-derived growth factor (PDGF) and PDGF a- and ß-receptors in the peripheral nervous system: an analysis of sciatic nerve and dorsal root ganglia. Dev. Biol. 155, 459-470 (1993 (Pubitemid 23076005)
51. Heldin, C. H. & Westermark, B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 79, 1283-1316 (1999 (Pubitemid 29473317)
52. Peulve, P., Laquerriere, A., Paresy, M., Hemet, J. & Tadie, M. Establishment of adult rat Schwann cell cultures: effect of b-FGF, a-MSH, NGF, PDGF, and TGF-ß on cell cycle. Exp. Cell Res. 214, 543-550 (1994 (Pubitemid 24310813)
53. Monje, P. V. et al. Non-antagonistic relationship between mitogenic factors and cAMP in adult Schwann cell re-differentiation. Glia 57, 947-961 (2009
54. Maudsley, S. et al. Platelet-derived growth factor receptor association with Na+/H+ exchanger regulatory factor potentiates receptor activity. Mol. Cell Biol. 20, 8352-8363 (2000
55. Reczek, D., Berryman, M. & Bretscher, A. Identification of EBP50: a PDZ-containing phosphoprotein that associates with members of the ezrin-radixin-moesin family. J. Cell Biol. 139, 169-179 (1997 (Pubitemid 27444089)
56. Murthy, A. et al. NHE-RF, a regulatory cofactor for Na+-H+ exchange, is a common interactor for merlin and ERM (MERM) proteins. J. Biol. Chem. 273, 1273-1276 (1998 (Pubitemid 28133639)
57. James, M. F., Beauchamp, R. L., Manchanda, N., Kazlauskas, A. & Ramesh, V. A NHERF binding site links the ßPDGFR to the cytoskeleton and regulates cell spreading and migration. J. Cell Sci. 117, 2951-2961 (2004 (Pubitemid 39117670)
58. Fraenzer, J. T. et al. Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int. J. Oncol. 23, 1493-1500 (2003
59. Previtali, S. C. et al. Schwann cells synthesize a7ß1 integrin which is dispensable for peripheral nerve development and myelination. Mol. Cell Neurosci. 23, 210-218 (2003 (Pubitemid 36703157)
60. Berti, C., Nodari, A., Wrabetz, L. & Feltri, M. L. Role of integrins in peripheral nerves and hereditary neuropathies. Neuromol. Med. 8, 191-204 (2006
61. Hermanson, M. et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 52, 3213-3219 (1992
62. Obremski, V. J., Hall, A. M. & Fernandez-Valle, C. Merlin, the neurofibromatosis type 2 gene product, and ß1 integrin associate in isolated and differentiating Schwann cells. J. Neurobiol. 37, 487-501 (1998 (Pubitemid 28549213)
63. Baron, V. & Schwartz, M. Cell adhesion regulates ubiquitin-mediated degradation of the platelet-derived growth factor receptor ß. J. Biol. Chem. 275, 39318-39323 (2000 (Pubitemid 32058953)
64. Miyamoto, S. et al. Integrin function: molecular hierarchies of cytoskeletal and signaling molecules. J. Cell Biol. 131, 791-805 (1995
65. Uhrbom, L., Hesselager, G., Ostman, A., Nister, M. & Westermark, B. Dependence of autocrine growth factor stimulation in platelet-derived growth factor-B-induced mouse brain tumor cells. Int. J. Cancer 85, 398-406 (2000 (Pubitemid 30030415)
66. Lokker, N. A., Sullivan, C. M., Hollenbach, S. J., Israel, M. A. & Giese, N. A. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res. 62, 3729-3735 (2002 (Pubitemid 34728854)
67. Servidei, T., Riccardi, A., Sanguinetti, M., Dominici, C. & Riccardi, R. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation. J. Cell. Physiol. 208, 220-228 (2006 (Pubitemid 43849008)
68. Smith, J. S., Lal, A., Harmon-Smith, M., Bollen, A. W. & McDermott, M. W. Association between absence of epidermal growth factor receptor immunoreactivity and poor prognosis in patients with atypical meningioma. J. Neurosurg. 106, 1034-1040 (2007 (Pubitemid 46871117)
69. Yang, S. Y. & Xu, G. M. Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas. J. Clin. Neurosci. 8 (Suppl. 1), 49-53 (2001
70. Hilton, D. A., Ristic, N. & Hanemann, C. O. Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ. Histopathology 55, 744-749 (2009
71. Utermark, T., Kaempchen, K. & Hanemann, C. O. Pathological adhesion of primary human schwannoma cells is dependent on altered expression of integrins. Brain Pathol. 13, 352-363 (2003 (Pubitemid 36975825)
72. Bello, L. et al. aVß3 and aVß5 integrin expression in meningiomas. Neurosurgery 47, 1185-1195 (2000
73. Wang, Y., Ji, Q. S., Mulvihill, M. & Pachter, J. A. Inhibition of the IGF-I receptor for treatment of cancer. Kinase inhibitors and monoclonal antibodies as alternative approaches. Recent Results Cancer Res. 172, 59-76 (2007
74. Clark, J. W., Eder, J. P., Ryan, D., Lathia, C. & Lenz, H. J. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin. Cancer Res. 11, 5472-5480 (2005 (Pubitemid 41060823)
75. Ammoun, S., Schmid, M. C., Triner, J., Manley, P. & Hanemann, C. O. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. Neuro Oncol. (in press
76. Adjei, A. A. et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 26, 2139-2146 (2008
77. Yeh, T. C. et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res. 13, 1576-1583 (2007 (Pubitemid 46450450)
78. Anlar, B., Sullivan, K. A. & Feldman, E. L. Insulin-like growth factor-I and central nervous system development. Horm. Metab. Res. 31, 120-125 (1999 (Pubitemid 29169485)
79. Russo, V. C., Gluckman, P. D., Feldman, E. L. & Werther, G. A. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr. Rev. 26, 916-943 (2005 (Pubitemid 41770158)
80. Myers, M. G. Jr et al. Insulin receptor substrate-1 mediates phosphatidylinositol 3'-kinase and p70S6k signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation. J. Biol. Chem. 269, 28783-28789 (1994
81. Mirsky, R. et al. Schwann cells as regulators of nerve development. J. Physiol. Paris 96, 17-24 (2002 (Pubitemid 34087029)
82. Cheng, H. L. et al. Characterization of insulin-like growth factor-I and its receptor and binding proteins in transected nerves and cultured Schwann cells. J. Neurochem. 66, 525-536 (1996
83. Stewart, H. J. et al. Regulation of rat Schwann cell Po expression and DNA synthesis by insulin-like growth factors in vitro. Eur. J. Neurosci. 8, 553-564 (1996
84. Russell, J. W., Cheng, H. L. & Golovoy, D. Insulin-like growth factor-I promotes myelination of peripheral sensory axons. J. Neuropathol. Exp. Neurol. 59, 575-584 (2000 (Pubitemid 30457788)
85. Hofmann, F. & Garcia-Echeverria, C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov. Today 10, 1041-1047 (2005 (Pubitemid 41074142)
86. Rodon, J., DeSantos, V., Ferry, R. J. Jr & Kurzrock, R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol. Cancer Ther. 7, 2575-2588 (2008
87. Shinkaruk, S., Bayle, M., Lain, G. & Deleris, G. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr. Med. Chem. Anticancer Agents 3, 95-117 (2003 (Pubitemid 36221732)
88. Nussenbaum, F. & Herman, I. M. Tumor angiogenesis: insights and innovations. J. Oncol. 2010, 132641 (2010
89. Pilch, H. et al. Hypoxia-stimulated expression of angiogenic growth factors in cervical cancer cells and cervical cancer-derived fibroblasts. Int. J. Gynecol. Cancer 11, 137-142 (2001 (Pubitemid 32381662)
90. Ellis, L. M. The role of neuropilins in cancer. Mol. Cancer Ther. 5, 1099-1107 (2006 (Pubitemid 43881301)
91. Plotkin, S. R. et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N. Engl. J. Med. 361, 358-367 (2009
92. Caye-Thomasen, P. et al. VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol. Neurotol. 26, 98-101 (2005 (Pubitemid 40130217)
93. Uesaka, T. et al. Expression of VEGF and its receptor genes in intracranial schwannomas. J. Neurooncol. 83, 259-266 (2007 (Pubitemid 46952236)
94. Zhu, Z. et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia 17, 604-611 (2003 (Pubitemid 36395655)
95. Xue, Y. et al. Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proc. Natl Acad. Sci. USA 105, 18513-18518 (2008
96. Zhu, Z. & Witte, L. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest. New Drugs 17, 195-212 (1999 (Pubitemid 30037954)
97. Yagi, Y. et al. Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice. Cancer Chemother. Pharmacol. 66, 745-753 (2010
98. Huynh, H., Chow, P. K. & Soo, K. C. AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. Mol. Cancer Ther. 6, 2468-2476 (2007 (Pubitemid 47480412)
99. Weller, M. & Stupp, R. Approval of new drugs for glioblastoma. Curr. Opin. Neurol. 22, 617-618 (2009
100. Rouleau, G. A. et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363, 515-521 (1993 (Pubitemid 23186636)
101. Bretscher, A., Edwards, K. & Fehon, R. G. ERM proteins and merlin: integrators at the cell cortex. Nat. Rev. Mol. Cell Biol. 3, 586-599 (2002
102. McClatchey, A. I. & Fehon, R. G. Merlin and the ERM proteins-regulators of receptor distribution and signaling at the cell cortex. Trends Cell Biol. 19, 198-206 (2009
103. Li, W. et al. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4DCAF1 in the nucleus. Cell 140, 477-490 (2010
104. Evans, D. G. et al. Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin. Cancer Res. 15, 5032-5039 (2009
105. Leu, T. H. & Maa, M. C. Tyr-863 phosphorylation enhances focal adhesion kinase autophosphorylation at Tyr-397. Oncogene 21, 6992-7000 (2002
106. Schlaepfer, D. D. & Hunter, T. Focal adhesion kinase overexpression enhances ras-dependent integrin signaling to ERK2/mitogen-activated protein kinase through interactions with and activation of c-Src. J. Biol. Chem. 272, 13189-13195 (1997 (Pubitemid 27216745)